Risk of Birth Defects Associated With Nelfinavir Exposure During Pregnancy
暂无分享,去创建一个
D. Covington | P. Doi | S. Conner | E. Daniels | J. Swinson
[1] Roger E. Stevenson,et al. Human Malformations and Related Anomalies , 2006 .
[2] J. Moodley,et al. Management of human immunodeficiency virus infection in pregnancy. , 2005, Best practice & research. Clinical obstetrics & gynaecology.
[3] J M Friedman,et al. Teratogenicity of Recently Introduced Medications in Human Pregnancy , 2002, Obstetrics and gynecology.
[4] H. Tilson,et al. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry , 2002, Pharmacoepidemiology and drug safety.
[5] M. Cheok,et al. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? , 2002, American journal of obstetrics and gynecology.
[6] W. Blattner,et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. , 2002 .
[7] P. Easterbrook,et al. Experience of nevirapine use in a London cohort of HIV‐infected pregnant women , 2001, HIV medicine.
[8] L. Paulozzi,et al. Evaluation of selected characteristics of pregnancy drug registries. , 1999, Teratology.
[9] B. Sha. Public Health Service Task Force Recommendations for the Use of Antiretrovial Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States , 1998 .